

09-11-2000

Gr 1633

PATENT
Attorney Docket No. 3935US



CERTIFICATE OF MAILING (under 37 C.F.R. § 1.10 if checked)
I hereby certify that this transmittal along with all items checked below is being deposited with the United States Postal Service
 as first class mail, postage prepaid (37 C.F.R. § 1.8)
 "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10
Express mail label mailing number: EL700253220US
on the date inserted below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Lynette Eliason
Typed name of person mailing transmittal

September 8, 2000
Date of Deposit

Lynette Eliason
Signature of person mailing transmittal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:	Michael C. Wilson	Group Art Unit No.:	1633
Applicant(s):	Fallaux et al.	Filing date:	July 19, 1999
Serial No.:	09/356,575	For (title):	PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS TO BE USED IN GENE THERAPY

RECEIVED

COMMUNICATION TRANSMITTAL

Commissioner for Patents
Washington, D.C. 20231

SEP 14 2000

TECH CENTER 1600/2900

Sir:

Enclosed for filing in connection with the above-identified patent application, and submitted in the order listed, are:

- Postcard receipt acknowledgment (attached to the front of this transmittal).
- Duplicate copy of this transmittal sheet in the event that additional filing fees are required under 37 C.F.R. § 1.16. Any such fees may be charged to deposit account no. 20-1469.
- Check no. in the amount of \$ for the presentation of extra claims as calculated in the remarks section below.
- Preliminary amendment.
- Amendment or other communication in response to the non-final office action mailed .
- Amendment or other communication under 37 C.F.R. § 1.116 in response to the final office action mailed .
- Petition for Extension of Time in duplicate with check no. in the amount of \$.
- Verified statement(s) to establish small entity status under 37 C.F.R. § 1.9 and 37 C.F.R. § 1.27 signed by (or on behalf of) .
- Information disclosure statement and information disclosure citation form PTO-1449 with copies of listed documents.
- Statement under 37 C.F.R. §§ 1.821(f); Paper copy of sequence listing; and CRF copy of sequence listing; Terminal disclaimer to obviate a double patenting rejection over a prior patent; and Statement under 37 CFR 3.73(b) with copy of assignment.

Remarks:

- An amendment has been made involving one or more claims in the application. The calculation to determine whether any additional fee is due is presented below.

1	2	3	\$EXTRA
Total claims	-	=	x 18.00 =
Indep. claims	-	=	x 78.00 =
First presentation of a multiple dep. claim (+260.00)			
SUBTOTAL			
Reduction for small entity - 50% of subtotal*			
TOTAL ADDITIONAL FEE (subtotal minus any reduction)			

*Verified statement(s) must be attached to support this reduction if small entity status has not been previously established.

1 Claims remaining after amendment.

2 Highest number of claims previously paid for. Not less than 20 for total claims and 3 for independent claims.

3 Difference between claims remaining and highest number previously paid for. If less than zero, enter "0."

- The commissioner is authorized to charge any additional fees required but not submitted with any document or request requiring fee payment under 37 C.F.R. §§ 1.16 and 1.17 to deposit account no. 20-1469 during the entire pendency of this application.

Respectfully submitted,

Allen C. Turner
Allen C. Turner
Reg. No. 33,041
TRASK BRITT
P.O. Box 2550
Salt Lake City, UT 84110-2550
(801) 532-1922

Date: September 8, 2000
Enclosures: As identified above